Study of abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ) in metastatic castrate resistant prostate cancer patients

Trial Profile

Study of abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ) in metastatic castrate resistant prostate cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Feb 2017 Results (n=2540) presented at the 2017 Genitourinary Cancers Symposium.
    • 16 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top